Benzinga | May 26, 2021 07:58AM EDT

Morgan Stanley Maintains Overweight on Axsome Therapeutics, Raises Price Target to $105

Morgan Stanley analyst Vikram Purohit maintains Axsome Therapeutics (NASDAQ:AXSM) with a Overweight and raises the price target from $104 to $105.